Effectiveness of magnesium sulphate, lignocaine and dexmedetomidine in attenuating the stress response during tracheal extubation- prospective randomized study

Effect of Magnesium sulphate,Lidocaine and Dexmedetomidine on tracheal extubation response in patients under General anaesthesia - A double blinded randomised comparative prospective study - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096508

Enrollment

150

Registered

2025-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Magnesium sulphate: Magnesium sulphate 30 milligrams per kg body weight shall be administered once the last stitch on the skin is placed by the surgeon the last painful stimulus of the

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing elective oncosurgery under general anaesthesia ASA grade I and II Mallampati grade I or II

Exclusion criteria

Exclusion criteria: History of Asthma or COPD Substance abuse, smoking , sedatives Active airway infection or history of tracheal or laryngeal surgery

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of intravenous magnesium sulphate, lidocaine and dexmedetomidine in attenuating (1) Hemodynamic responses ( Heart rate and blood pressure ) during tracheal extubation (2) Tracheal responses ( bucking, coughing and desaturation) during tracheal extubationTimepoint: (1) Immediately before extubation (2) Immediately after extubation (3) Every 5minutes for first 60 minutes and 2 hours after extubation	—

Measure

Time frame

To compare the efficacy of intravenous magnesium sulphate, lidocaine and dexmedetomidine in attenuating (1) Hemodynamic responses ( Heart rate and blood pressure ) during tracheal extubation (2) Tracheal responses ( bucking, coughing and desaturation) during tracheal extubationTimepoint: (1) Immediately before extubation (2) Immediately after extubation (3) Every 5minutes for first 60 minutes and 2 hours after extubation

—

Secondary

Measure	Time frame
To evaluate the time to extubation & recovery characteristics To assess sedation levels post extubation To monitor any adverse effects related to these agentsTimepoint: (1) Immediately after extubation (2) Every 5minutes for first 60 minutes & 2 hours after extubation	—

Countries

India

Contacts

Public ContactDr Ajith K N

Kidwai Memorial Institute of Oncology

drmamathah@yahoo.com7624815394

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026